MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling

Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138−CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis

(2016) M Martello et al.   LEUKEMIA

Deletions linked to TP53 loss drive cancer through p53-independent mechanisms

(2016) Yu Liu et al.   NATURE

CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy

(2016) Emily Foran et al.   NEUROBIOLOGY OF DISEASE

miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma

(2015) Y. Yang et al.   CLINICAL CANCER RESEARCH

MiR-324-5p Suppresses Hepatocellular Carcinoma Cell Invasion by Counteracting ECM Degradation through Post-Transcriptionally Downregulating ETS1 and SP1

(2015) Liangqi Cao et al.   PLoS One

MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma

(2015) Juan Du et al.   Oncotarget

Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients

(2015) Emilia L Lim et al.   GENOME BIOLOGY

A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance

(2014) Z. Liu et al.   BLOOD

miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway

(2014) Jian-Jun Zhao et al.   CANCER RESEARCH

Roles for Hedgehog signaling in adult organ homeostasis and repair

(2014) R. Petrova et al.   DEVELOPMENT

Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression–Related Death

(2014) Philippe Moreau et al.   JOURNAL OF CLINICAL ONCOLOGY

Dysregulation of the MiR-324-5p-CUEDC2 Axis Leads to Macrophage Dysfunction and Is Associated with Colon Cancer

(2014) Yuan Chen et al.   Cell Reports

Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1

(2013) Teresa S. Hawley et al.   AMERICAN JOURNAL OF HEMATOLOGY

RAR 2 expression confers myeloma stem cell features

(2013) Y. Yang et al.   BLOOD

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

(2013) Robert O’Connor et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma

(2012) S. Blotta et al.   BLOOD

miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF

(2012) Chun-Yan Sun et al.   CARCINOGENESIS

microRNAs in cancer management

(2012) Yi W Kong et al.   LANCET ONCOLOGY

B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells

(2012) M P Puissegur et al.   LEUKEMIA

Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors

(2012) A Ikegame et al.   LEUKEMIA

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

(2011) J. Jakubikova et al.   BLOOD

Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma

(2011) Sikander Ailawadhi et al.   LEUKEMIA & LYMPHOMA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

(2010) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

(2009) D. Reece et al.   BLOOD

Role of Active Drug Transporters in Refractory Multiple Myeloma

(2009) Marco Tucci et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA

Overexpression of hedgehog pathway molecules and FOXM1 in non-small cell lung carcinomas

(2009) Ioannis P. Gialmanidis et al.   LUNG CANCER

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

(2009) Shaji K. Kumar et al.   MAYO CLINIC PROCEEDINGS

Causes and consequences of microRNA dysregulation in cancer

(2009) Carlo M. Croce   NATURE REVIEWS GENETICS

The Hedgehog Pathway and Pancreatic Cancer

(2009) Manuel Hidalgo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

(2008) W. Matsui et al.   CANCER RESEARCH

Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells

(2008) Elisabetta Ferretti et al.   EMBO JOURNAL

Myeloid cell differentiation arrest by miR-125b-1 in myelodysplasic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation

(2008) Marina Bousquet et al.   JOURNAL OF EXPERIMENTAL MEDICINE